- Drug Pipelines
- June 2024
- 180 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- January 2022
- 278 Pages
Global
From €3868EUR$4,250USD£3,316GBP
- Report
- September 2023
- 120 Pages
North America
From €5415EUR$5,950USD£4,642GBP
- Report
- October 2021
- 100 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- August 2022
- 100 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 125 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- May 2022
- 163 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- March 2022
- 180 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- October 2023
- 129 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Hydromorphone is an opioid analgesic used to treat moderate to severe pain. It is a semi-synthetic opioid derived from morphine and is available in both oral and injectable forms. It is commonly used in hospitals and other medical settings to treat pain, and is also available in some countries as an over-the-counter medication. Hydromorphone is a Schedule II controlled substance in the United States, meaning it has a high potential for abuse and addiction.
Hydromorphone is a popular choice for pain relief due to its fast-acting effects and its ability to provide long-lasting relief. It is also used in combination with other analgesics to provide more effective pain relief. Common side effects of hydromorphone include nausea, dizziness, constipation, and drowsiness.
In the analgesics market, hydromorphone is a major player. It is widely used in hospitals and other medical settings, as well as in some countries as an over-the-counter medication. It is also used in combination with other analgesics to provide more effective pain relief.
Some companies in the hydromorphone market include Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals, and Mylan Pharmaceuticals. Show Less Read more